Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:52:49.119Z.
Calculation as of: 2026-10-06T16:52:49.119Z.
Quote observation: 2026-10-06T16:50:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 310997c20848bd5012eb98bb82f11fa46ca59880ef1b58a452bebfeaa3e5ded1
PE RATIO
N/A
Market Cap
$536.98M
PE Ratio
1196.54
TTM Avg
806.49
3Y Avg
715.80
5Y Avg
715.80
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $538.99M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $540.83M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $536.98M | 1196.54 | 806.49 | 715.80 | 715.80 |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $543.67M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $544.79M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $525.76M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $521.82M | N/A | N/A | N/A | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $517.30M | N/A | 0.20 | 0.20 | 0.20 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$6.66
Forward EPS (Est.)
$-0.71
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
